title: Treatment of dyspareunia secondary to vulvovaginal atrophy.
abstract: Declining estrogen levels associated with menopause can result in vulvovaginal atrophy and some degree of dyspareunia for more than half of all women in menopause. In 2013, the U.S. Food and Drug Administration approved ospemifene, a nonhormonal oral medication for the treatment of dyspareunia in menopause. This article will provide an overview of ospemifene and its indications, side effects and implications for nurses.
authors.forename: Heidi Collins
authors.initials: HC
authors.lastname: Fantasia
mesh_terms: D000284:Administration, Oral; D001284:Atrophy; D004347:Drug Interactions; D004414:Dyspareunia / Q000188:drug therapy* / Q000209:etiology / Q000451:nursing; D005260:Female; D006801:Humans; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome; D014621:Vagina / Q000473:pathology*; D014844:Vulva / Q000473:pathology*
chemical_list: D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; C119141:Ospemifene
keywords: dyspareunia; menopause; ospemifene; painful intercourse; vaginal atrophy